1
Elena Feinstein, Igor Mett: Therapeutic uses of inhibitors of RTP801L. Quark Pharmaceuticals, John P White, Cooper & Dunham, December 1, 2009: US07626015 (74 worldwide citation)

The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.


2
David Wallach, Mark Boldin, Igor Mett, Eugene Varfolomeev: Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors. Yeda Research and Development, Browdy and Neimark P L L C, June 17, 2003: US06579697 (16 worldwide citation)

The present invention generally concerns novel proteins which bind to the intracellular domains of the p55 and p75 TNF-Rs and the FAS-R, which are capable of modulating the function of the p55 and p75 TNF-Rs and the FAS-R, and the DNA sequences which encode them. The present invention also concerns ...


3
David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann: TNF ligands. Yeda Research and Development, Browdy and Neimark, May 15, 2001: US06232446 (8 worldwide citation)

Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-term ...


4
Elena Feinstein, Igor Mett: Therapeutic uses of inhibitors of RTP801L. Quark Pharmaceuticals, John P White, Cooper & Dunham, September 13, 2011: US08017764 (7 worldwide citation)

The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.


5
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu: Retinoid-liposomes for treating fibrosis. Nitto Denko Corporation, Baker & Hostetler, June 3, 2014: US08741867 (7 worldwide citation)

What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID ...


6
Elena Feinstein, Evgenia Alpert, Igor Mett, Hagar Kalinski, Amir Bar Ilan, Igor Spivak, Natanja Slager: Methods for treating eye disorders. Quark Pharmaceuticals, Fish & Richardson P C, September 1, 2015: US09121020 (7 worldwide citation)

The present invention relates to compositions and methods for inhibiting loss of a retinal ganglion cell in a subject, comprising non-invasively applying to the surface of the eye of the subject an ophthalmic composition comprising a therapeutically effective amount of at least one siRNA which down ...


7
David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann: TNF receptor-specific antibodies. Yeda Research and Development, Browdy and Neimark, July 17, 2001: US06262239 (7 worldwide citation)

Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth c ...


8
Yoshiro Niitsu, Victor Knopov, Joseph E Payne, Richard P Witte, Mohammad Ahmadian, Loren A Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu: Retinoid-liposomes for enhancing modulation of HSP47 expression. Nitto Denko Corporation, Baker & Hostetler, March 4, 2014: US08664376 (6 worldwide citation)

What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1—2 (SEQ ID NOS: 60 and 127), SERPINH1—45a (SEQ ID ...


9
David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann: Method of inhibiting the cytocidal effect of TNF with TNF receptor-specific antibodies. Yeda Research and Development, Browdy and Neimark P L L C, April 29, 2003: US06555111 (6 worldwide citation)

Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth c ...


10
David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann: DNA molecule encoding TNF binding ligands and vectors and host cells containing the DNA molecule. Yeda Research and Development, Browdy and Neimark P L L C, August 5, 2003: US06602993 (5 worldwide citation)

DNA encoding Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p ...